Halozyme Therapeutics (HALO) Tops Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $108.17 +1.93%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.02, $0.11 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $43.4 million versus the consensus estimate of $25.12 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- CoStar Group acquires Zonda for $800M, adding new home data
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
